Literature DB >> 28529984

No benefit from ramucirumab in first-line chemotherapy?

Seiichiro Mitani1, Kei Muro1.   

Abstract

Entities:  

Year:  2017        PMID： 28529984      PMCID： PMC5420525          DOI： 10.21037/tgh.2017.03.18

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  18 in total

1.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Authors:  Josep Tabernero; Takayuki Yoshino; Allen Lee Cohn; Radka Obermannova; Gyorgy Bodoky; Rocio Garcia-Carbonero; Tudor-Eliade Ciuleanu; David C Portnoy; Eric Van Cutsem; Axel Grothey; Jana Prausová; Pilar Garcia-Alfonso; Kentaro Yamazaki; Philip R Clingan; Sara Lonardi; Tae Won Kim; Lorinda Simms; Shao-Chun Chang; Federico Nasroulah
Journal:  Lancet Oncol       Date:  2015-04-12       Impact factor: 41.316

2.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

Authors:  Aimery de Gramont; Eric Van Cutsem; Hans-Joachim Schmoll; Josep Tabernero; Stephen Clarke; Malcolm J Moore; David Cunningham; Thomas H Cartwright; J Randolph Hecht; Fernando Rivera; Seock-Ah Im; György Bodoky; Ramon Salazar; Frédérique Maindrault-Goebel; Einat Shacham-Shmueli; Emilio Bajetta; Martina Makrutzki; Aijing Shang; Thierry André; Paulo M Hoff
Journal:  Lancet Oncol       Date:  2012-11-16       Impact factor: 41.316

3.  Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Authors:  Jaafar Bennouna; Javier Sastre; Dirk Arnold; Pia Österlund; Richard Greil; Eric Van Cutsem; Roger von Moos; Jose Maria Viéitez; Olivier Bouché; Christophe Borg; Claus-Christoph Steffens; Vicente Alonso-Orduña; Christoph Schlichting; Irmarie Reyes-Rivera; Belguendouz Bendahmane; Thierry André; Stefan Kubicka
Journal:  Lancet Oncol       Date:  2012-11-16       Impact factor: 41.316

4.  Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

Authors:  Rachel S Kerr; Sharon Love; Eva Segelov; Elaine Johnstone; Beverly Falcon; Peter Hewett; Andrew Weaver; David Church; Claire Scudder; Sarah Pearson; Patrick Julier; Francesco Pezzella; Ian Tomlinson; Enric Domingo; David J Kerr
Journal:  Lancet Oncol       Date:  2016-09-19       Impact factor: 41.316

5.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Authors:  Edward B Garon; Tudor-Eliade Ciuleanu; Oscar Arrieta; Kumar Prabhash; Konstantinos N Syrigos; Tuncay Goksel; Keunchil Park; Vera Gorbunova; Ruben Dario Kowalyszyn; Joanna Pikiel; Grzegorz Czyzewicz; Sergey V Orlov; Conrad R Lewanski; Michael Thomas; Paolo Bidoli; Shaker Dakhil; Steven Gans; Joo-Hang Kim; Alexandru Grigorescu; Nina Karaseva; Martin Reck; Federico Cappuzzo; Ekaterine Alexandris; Andreas Sashegyi; Sergey Yurasov; Maurice Pérol
Journal:  Lancet       Date:  2014-06-02       Impact factor: 79.321

6.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

7.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316

8.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

9.  Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

Authors:  H H Yoon; J C Bendell; F S Braiteh; I Firdaus; P A Philip; A L Cohn; N Lewis; D M Anderson; E Arrowsmith; J D Schwartz; L Gao; Y Hsu; Y Xu; D Ferry; S R Alberts; Z A Wainberg
Journal:  Ann Oncol       Date:  2016-10-20       Impact factor: 51.769

10.  Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.

Authors:  Thomas Crosby; Christopher N Hurt; Stephen Falk; Simon Gollins; Somnath Mukherjee; John Staffurth; Ruby Ray; Nadim Bashir; John A Bridgewater; J Ian Geh; David Cunningham; Jane Blazeby; Rajarshi Roy; Tim Maughan; Gareth Griffiths
Journal:  Lancet Oncol       Date:  2013-04-25       Impact factor: 41.316
View more
  1 in total

Review 1.  Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients' decision making?

Authors:  Stavros Gkolfinopoulos; Demetris Papamichael; Konstantinos Papadimitriou; Panos Papanastasopoulos; Vassilios Vassiliou; Panteleimon Kountourakis
Journal:  World J Gastrointest Oncol       Date:  2018-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.